论文部分内容阅读
目的探讨大肠癌患者血清中多项肿瘤标志物检测的意义。方法选择1 645例肠道疾病患者,其中肠道良性疾病组患者1 028例(B组),大肠癌患者617例(C组),选择1 609例健康体检者为对照组(A组),采用化学发光分析仪检测糖类抗原199(CA19-9)、癌胚抗原(CEA)、前列腺特异抗原(T-PSA);采用MAGLUMI4000分析仪检测糖类抗原242(CA242)、胃癌相关抗原724(CA72-4)、癌抗原50(CA50)、神经元特异性烯醇化酶(NSE)。结果与A组、B组比较,C组患者CA242、CA72-4、CA50、CA19-9、CEA水平均显著上升,差异均有统计学意义(P<0.05);B组与A组各指标比较,差异无统计学意义(P>0.05);C组患者CA242增多占70.99%、CA72-4增多占29.34%、CA50增多占69.04%、CA19-9增多占91.90%、CEA增多占68.88%、NSE增多占40.19%、T-PSA增多占52.67%、联合测定增多占94.00%。结论多项肿瘤标志物联合测定,可提高对大肠癌患者鉴别诊断准确性,对进一步诊治、预后具有重要临床意义。
Objective To explore the significance of detection of multiple tumor markers in serum of patients with colorectal cancer. Methods A total of 1 645 cases of intestinal diseases were enrolled in this study, including 1028 cases of benign intestinal diseases (group B) and 617 cases of colorectal cancer (group C). A total of 1 609 healthy subjects were selected as the control group (group A) (CA19-9), carcinoembryonic antigen (CEA) and prostate-specific antigen (T-PSA) were detected by chemiluminescence analyzer. The antigen of carbohydrate antigen 242 (CA242), gastric cancer associated antigen 724 CA72-4), cancer antigen 50 (CA50), neuron specific enolase (NSE). Results Compared with group A and group B, the levels of CA242, CA72-4, CA50, CA19-9 and CEA in group C were significantly increased (P <0.05), and those in group B and group A , The difference was not statistically significant (P> 0.05). In C group, CA242 increased more than 70.99%, CA72-4 increased 29.34%, CA50 increased 69.04%, CA19-9 increased 91.90%, CEA increased 68.88%, NSE Increased 40.19%, T-PSA increased 52.67%, combined measurement increased 94.00%. Conclusion The combination of a number of tumor markers can improve the accuracy of differential diagnosis of patients with colorectal cancer, and has important clinical significance for further diagnosis and prognosis.